News
MRUS
45.04
+0.24%
0.11
Weekly Report: what happened at MRUS last week (0415-0419)?
Weekly Report · 4d ago
RSI Alert: Merus (MRUS) Now Oversold
NASDAQ · 04/16 20:26
Weekly Report: what happened at MRUS last week (0408-0412)?
Weekly Report · 04/15 11:44
Merus Price Target Maintained With a $66.00/Share by Needham
Dow Jones · 04/11 09:52
Needham Reiterates Buy on Merus, Maintains $66 Price Target
Benzinga · 04/11 09:42
Analysts Have Conflicting Sentiments on These Healthcare Companies: ZimVie Inc (ZIMV) and Merus (MRUS)
TipRanks · 04/11 09:40
Merus Presents Preclinical Data Demonstrating Efficacy Of Zeno In Cancer Models With High NRG1 Expression At The AACR Annual Meeting 2024
Merus announced preclinical data on zenocutuzumab in cancer models with high neuregulin 1 (NRG1) expression were presented at the American Association of Cancer Research Annual Meeting 2024. Zeno, a HER2 × HER3 bispecific antibody, is effective in cancer model with high NRG1 expression. Merus is a clinical-stage oncology company developing innovative antibodies.
Benzinga · 04/08 16:03
Weekly Report: what happened at MRUS last week (0401-0405)?
Weekly Report · 04/08 11:50
Weekly Report: what happened at MRUS last week (0325-0329)?
Weekly Report · 04/01 11:47
Merus Initiated at Buy by Truist Securities
Dow Jones · 03/28 15:43
Truist Securities Initiates Coverage On Merus with Buy Rating, Announces Price Target of $69
Benzinga · 03/28 15:34
Weekly Report: what happened at MRUS last week (0318-0322)?
Weekly Report · 03/25 11:50
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
NASDAQ · 03/20 11:37
Weekly Report: what happened at MRUS last week (0311-0315)?
Weekly Report · 03/18 11:48
Analysts Offer Insights on Healthcare Companies: Geron (GERN), Merus (MRUS) and MoonLake Immunotherapeutics (MLTX)
TipRanks · 03/11 13:10
Weekly Report: what happened at MRUS last week (0304-0308)?
Weekly Report · 03/11 11:44
Analysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Merus (MRUS) and Eli Lilly & Co (LLY)
TipRanks · 03/11 11:10
Big Pharma patent cliffs seen fueling oncology M&A this year
Big Pharma patent cliffs seen fueling oncology M&A this year. Around $182B in revenue is at risk over the next four years due to patent expirations. Cantor Fitzgerald sees between five and 17 acquisition deals for oncologists in 2014. The global market for cancer drugs is expected to grow from $180B in 2022 to $323B in 2028.
Seeking Alpha · 03/10 17:08
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 03/08 10:21
3 Best Stocks to Buy Now, 3/8/2024, According to Top Analysts 
TipRanks · 03/08 07:05
More
Webull provides a variety of real-time MRUS stock news. You can receive the latest news about Merus through multiple platforms. This information may help you make smarter investment decisions.
About MRUS
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.